Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Leukemia through trial conditions or approval indications mapped to it or to one of its descendant entities.
26 drugs · 856 active trials
42 drugs · 1,287 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 3. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Neratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2016-10 |
| Pexidartinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 21, 2011 |
| Axicabtagene Ciloleucel | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 18, 2018 |
| BCR-ABL Inhibitor HS-10382 | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 26, 2024 |
| CTX-712 | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 25, 2023 |
| Degarelix | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2012-12 |
| Elranatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 9, 2019 |
| Encorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 28, 2020 |
| Fedratinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 24, 2020 |
| Glofitamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 22, 2024 |
| Idecabtagene Vicleucel | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 18, 2018 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 25, 2019 |
| Mirdametinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 27, 2026 |
| Niacinamide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 25, 2022 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 27, 2017 |
| Tovorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 29, 2026 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 23 | 0 | — | — | 1999-06 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 13 | 0 | — | — | 1998-08 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | 1999-07 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2002-01 |
| Sunitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2006-09 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2004-03 |
| Alisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | Jul 11, 2008 |
| Belinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2006-05 |
| Mocetinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2005-02 |
| Bexarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2004-01 |
| Tamibarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2007-09 |
| Temozolomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2004-03 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2010-10 |
| Azathioprine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Nov 25, 2014 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-04 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1998-02 |
| Paclitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1997-05 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1999-08 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2012-07 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1997-10 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2010-07 |
| Tandutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-05 |
| Tislelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jun 29, 2016 |
| Vismodegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-02 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-03 |
| Axitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-12 |
| Bafetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-07 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-01 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 3, 2015 |
| Elotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 10, 2013 |
| Eprenetapopt | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 18, 2017 |
| Fadraciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 2, 2019 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-10 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-06 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.